Background. This study performed a meta-analysis to explore the clinical efficacy of creatine phosphate sodium (CPS) and/or vitamin C for viral myocarditis (VMC) in children, to provide guidance for its clinical treatment. Methods. A literature search was performed on PubMed, Web of Science, Embase, China National Knowledge Infrastructure, and Wanfang databases to obtain published clinical randomized controlled trials (RCTs) on CPS and/or vitamin C for VMC in children, with a time span from 2013 to 2022. Relevant data was extracted and meta-analysis was performed using the statistical software Stata 16.0. Results. A total of 723 studies were retrieved and 19 studies were finally included for meta-analysis, with a total of 1,957 patients. The meta-analysis results showed that the observation group (conventional treatment + CPS and/or vitamin C) was superior to the control group (conventional treatment alone) in treatment effective rate (
OR
=
3.60
, 95% CI (2.55, 5.07), and
P
<
0.001
). Additionally, the observation group had lower levels of cardiac troponin-I (SMD = − 2.63, 95% CI (− 3.51, − 1.76), and
P
<
0.001
), creatine kinase isoenzyme (
SMD
=
−
2.78
, 95% CI (− 3.53, − 2.03), and
P
<
0.001
), lactate dehydrogenase (
SMD
=
−
1.95
, 95% CI (− 2.49, − 1.42), and
P
<
0.001
), aspartate aminotransferase (
SMD
=
−
0.87
, 95% CI (− 1.84, 0.09), and
P
=
0.076
), tumor necrosis factor-α (
SMD
=
−
3.90
, 95% CI (− 4.47, − 3.06), and
P
<
0.001
), and higher superoxide dismutase levels (
SMD
=
2.48
, 95% CI (1.64, 3.33), and
P
<
0.001
). Except aspartate aminotransferase, there were significant differences between the two groups in the other parameters. Conclusion. CPS and/or vitamin C treatment could greatly improve the treatment, protect myocardial function, and relieve inflammatory response in children with VMC.